AU2019413366B2 - Anti-CTLA-4 binding proteins and methods of use thereof - Google Patents

Anti-CTLA-4 binding proteins and methods of use thereof Download PDF

Info

Publication number
AU2019413366B2
AU2019413366B2 AU2019413366A AU2019413366A AU2019413366B2 AU 2019413366 B2 AU2019413366 B2 AU 2019413366B2 AU 2019413366 A AU2019413366 A AU 2019413366A AU 2019413366 A AU2019413366 A AU 2019413366A AU 2019413366 B2 AU2019413366 B2 AU 2019413366B2
Authority
AU
Australia
Prior art keywords
seq
antibody
ctla
cdr3
abp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019413366A
Other languages
English (en)
Other versions
AU2019413366A1 (en
Inventor
Adam Shultz Adler
Michael ASENSIO
David Scott Johnson
Yoong Wearn LIM
Rena Aviva Mizrahi
Erica Lyn STONE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gigagen Inc
Original Assignee
Gigagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gigagen Inc filed Critical Gigagen Inc
Publication of AU2019413366A1 publication Critical patent/AU2019413366A1/en
Application granted granted Critical
Publication of AU2019413366B2 publication Critical patent/AU2019413366B2/en
Priority to AU2025223772A priority Critical patent/AU2025223772A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2019413366A 2018-12-27 2019-12-27 Anti-CTLA-4 binding proteins and methods of use thereof Active AU2019413366B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025223772A AU2025223772A1 (en) 2018-12-27 2025-08-27 Anti-CTLA-4 binding proteins and methods of use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862785659P 2018-12-27 2018-12-27
US62/785,659 2018-12-27
PCT/US2019/068820 WO2020140084A1 (en) 2018-12-27 2019-12-27 Anti-ctla-4 binding proteins and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025223772A Division AU2025223772A1 (en) 2018-12-27 2025-08-27 Anti-CTLA-4 binding proteins and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2019413366A1 AU2019413366A1 (en) 2021-08-12
AU2019413366B2 true AU2019413366B2 (en) 2025-06-05

Family

ID=71126610

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019413366A Active AU2019413366B2 (en) 2018-12-27 2019-12-27 Anti-CTLA-4 binding proteins and methods of use thereof
AU2025223772A Pending AU2025223772A1 (en) 2018-12-27 2025-08-27 Anti-CTLA-4 binding proteins and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025223772A Pending AU2025223772A1 (en) 2018-12-27 2025-08-27 Anti-CTLA-4 binding proteins and methods of use thereof

Country Status (12)

Country Link
US (1) US12421311B2 (enExample)
EP (1) EP3902821A4 (enExample)
JP (3) JP7558949B2 (enExample)
KR (1) KR20210121045A (enExample)
CN (2) CN114008071B (enExample)
AU (2) AU2019413366B2 (enExample)
BR (1) BR112021012588A2 (enExample)
CA (1) CA3124961C (enExample)
IL (2) IL316757A (enExample)
MX (1) MX2021007848A (enExample)
SG (1) SG11202106764YA (enExample)
WO (1) WO2020140084A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250157457A (ko) * 2015-10-23 2025-11-04 메뤼스 엔.페. 암 성장을 억제하는 결합 분자
IL316757A (en) 2018-12-27 2025-01-01 Gigagen Inc Anti-CTLA-4 binding proteins and methods of using them
AU2021299338A1 (en) * 2020-07-02 2023-02-23 Gigagen, Inc. Anti-CTLA-4 binding proteins and methods of use thereof
AU2021411581A1 (en) * 2020-12-31 2023-07-06 Novarock Biotherapeutics, Ltd. Antibodies to tnfr2 and uses thereof
EP4362981A1 (en) * 2021-07-02 2024-05-08 Gigagen, Inc. Anti-ctla-4 binding proteins and methods of use thereof
KR20240114766A (ko) * 2021-12-10 2024-07-24 머크 샤프 앤드 돔 엘엘씨 인간 메소텔린 결합제
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006029219A2 (en) * 2004-09-08 2006-03-16 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
US20130136749A1 (en) * 1999-08-24 2013-05-30 Medarex, Inc. Human CTLA-4 Antibodies And Their Uses
WO2017106372A1 (en) * 2015-12-15 2017-06-22 Oncoimmune, Inc. Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
US9714290B2 (en) * 2011-03-09 2017-07-25 Antitope Limited Humanised anti CTLA-4 antibodies
WO2017194265A1 (en) * 2016-05-10 2017-11-16 Agency For Science, Technology And Research Anti-CTLA-4 Antibodies
EP3256165A2 (en) * 2015-02-13 2017-12-20 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
WO2018209701A1 (en) * 2017-05-19 2018-11-22 Wuxi Biologics (Shanghai) Co., Ltd. Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ517202A (en) * 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US20110166335A1 (en) 2000-06-30 2011-07-07 Corbin David R Xenorhabdus sp. genome sequences and uses thereof
TWI320716B (en) * 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
WO2014089113A1 (en) 2012-12-03 2014-06-12 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
WO2015092394A1 (en) 2013-12-17 2015-06-25 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
JP6449338B2 (ja) * 2014-06-06 2019-01-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
SG11201708223QA (en) 2015-04-17 2017-11-29 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
SI3303394T1 (sl) * 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
WO2018157147A1 (en) 2017-02-27 2018-08-30 Dragonfly Therapeutics, Inc. Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
IL316757A (en) 2018-12-27 2025-01-01 Gigagen Inc Anti-CTLA-4 binding proteins and methods of using them
TWI850316B (zh) 2019-01-21 2024-08-01 法商賽諾菲公司 用於晚期實性瘤癌症之治療性rna及抗pd1抗體
AU2021299338A1 (en) 2020-07-02 2023-02-23 Gigagen, Inc. Anti-CTLA-4 binding proteins and methods of use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130136749A1 (en) * 1999-08-24 2013-05-30 Medarex, Inc. Human CTLA-4 Antibodies And Their Uses
WO2006029219A2 (en) * 2004-09-08 2006-03-16 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
US9714290B2 (en) * 2011-03-09 2017-07-25 Antitope Limited Humanised anti CTLA-4 antibodies
EP3256165A2 (en) * 2015-02-13 2017-12-20 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
WO2017106372A1 (en) * 2015-12-15 2017-06-22 Oncoimmune, Inc. Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
WO2017194265A1 (en) * 2016-05-10 2017-11-16 Agency For Science, Technology And Research Anti-CTLA-4 Antibodies
WO2018209701A1 (en) * 2017-05-19 2018-11-22 Wuxi Biologics (Shanghai) Co., Ltd. Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4)

Also Published As

Publication number Publication date
US20220064303A1 (en) 2022-03-03
IL284156B2 (en) 2025-04-01
MX2021007848A (es) 2021-10-26
EP3902821A1 (en) 2021-11-03
CN114008071B (zh) 2025-01-21
JP2022516071A (ja) 2022-02-24
JP2025128343A (ja) 2025-09-02
WO2020140084A1 (en) 2020-07-02
CA3124961A1 (en) 2020-07-02
JP7745669B2 (ja) 2025-09-29
IL284156A (en) 2021-08-31
SG11202106764YA (en) 2021-07-29
IL316757A (en) 2025-01-01
CN119930820A (zh) 2025-05-06
BR112021012588A2 (pt) 2021-09-08
KR20210121045A (ko) 2021-10-07
AU2019413366A1 (en) 2021-08-12
IL284156B1 (en) 2024-12-01
AU2025223772A1 (en) 2025-09-18
EP3902821A4 (en) 2022-11-30
CN114008071A (zh) 2022-02-01
US12421311B2 (en) 2025-09-23
JP2024042072A (ja) 2024-03-27
JP7558949B2 (ja) 2024-10-01
CA3124961C (en) 2025-11-25

Similar Documents

Publication Publication Date Title
AU2019413366B2 (en) Anti-CTLA-4 binding proteins and methods of use thereof
US20220064302A1 (en) Anti-PD-1 Binding Proteins and Methods of Use Thereof
WO2020140094A1 (en) Anti-b7-h3 binding proteins and methods of use thereof
JP7783840B2 (ja) 抗ｃｔｌａ－４結合タンパク質及びその使用方法
WO2020142626A1 (en) Anti-ox40 binding proteins and methods of use thereof
WO2022006555A2 (en) BISPECIFIC ANTIGEN BINDING PROTEINS TARGETING PD-L1 AND TGF-β AND METHODS OF USE
US20220056137A1 (en) Anti-PD-L1 Binding Proteins and Methods of Use Thereof
WO2020140070A1 (en) Anti-b7-h4 binding proteins and methods of use thereof
CA3249127A1 (en) Anti-ctla-4 binding proteins and methods of use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)